- Home
- CYN vs BRNS Comparison
CYN vs BRNS Comparison
Compare CYN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | BRNS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 24.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYN | BRNS |
|---|---|---|
| Price | $1.10 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 181.2K | 39.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $0.51 |
| 52 Week High | $8.83 | $1.83 |
Technical Indicators
Market Signals| Indicator | CYN | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 44.33 |
| Support Level | N/A | $0.56 |
| Resistance Level | $1.40 | $0.62 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.67 | 34.67 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.